Speakers
Ram Miller
Director Translational Medicine
Novartis
Day One
Wednesday, May 25th
4:00 pm | Considerations for Novel ALS Clinical Trials
Amir Lahav
Head of Digital R&D, Digital Healthcare Innovation
Mitsubishi Tanabe Pharma Holdings America
Day One
Wednesday, May 25th
9:00 am | Implementing Remote Monitoring Technology for Tracking ALS Outside the Clinic Using Wearable Sensors & Smartphone Apps
Andrew Wolff
Senior Vice President, Senior Fellow, Clinical Research & Development
Cytokinetics
Day One
Wednesday, May 25th
2:00 pm | Panel Discussion: Refining Sensitive Primary Outcome Measures & Navigating Innovative Trial Design in ALS
Angela Genge
Chief Medical Officer
QurAlis
Day One
Wednesday, May 25th
2:00 pm | Panel Discussion: Refining Sensitive Primary Outcome Measures & Navigating Innovative Trial Design in ALS
11:00 am | Exploring Electrophysiological Biomarkers of Diagnosis & Outcome in ALS
Dimitry Ofengeim
Head of Precision Neurology & Neuroinflammation Cluster
Sanofi
Day Two
Thursday, May 26th
1:30 pm | Investigating Pathways for Intervention: Targeting RIPK1 in ALS
11:00 am | Panel Discussion: Mechanisms, Targets, & Therapeutic Potential: Dissecting Exciting Opportunities to Drive Novel Therapeutic Strategies
Ferenc Tracik
Chief Medical Officer
NeuroSense Therapeutics
Day Two
Thursday, May 26th
9:00 am | From Monotherapy to Combination Therapy: Considering a Paradigm Shift to Target Complexity of ALS
James Berry
Chief, Division of ALS & Motor Neuron Diseases
Massachusetts General Hospital
Day One
Wednesday, May 25th
1:30 pm | Moving Beyond ALSFRS-R & Survival Endpoints: Exploring Patient Reported & Non-Traditional Outcome Measures
Jeremy Shefner
Professor & Chair of Neurology
Barrow Neurological Institute
Day One
Wednesday, May 25th
12:00 pm | Innovation in ALS Trial Design & Clinical Outcome Measures
Johanne Kaplan
Chief Development Officer
ProMIS Neurosciences
Day Two
Thursday, May 26th
11:00 am | Panel Discussion: Mechanisms, Targets, & Therapeutic Potential: Dissecting Exciting Opportunities to Drive Novel Therapeutic Strategies
Kasper Roet
Founder & Chief Executive Officer
QurAlis
Day Two
Thursday, May 26th
8:30 am | Harnessing New Insights into Human Genetics & Stem Cell Technology to Provide Genetically-Validated Targets for the Sporadic ALS Patient Populations
Leonard van den Berg
Professor of Neurology
University Medical Center Utrecht
Day One
Wednesday, May 25th
4:30 pm | TRICALS & the ENCALS Prediction Model: Innovating Clinical Trials in ALS
Mansuo Hayashi
Chief Scientific Officer
Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly
Sabrina Paganoni
Co-Director
Neurological Clinical Research Institute Massachusetts General Hospital
Day One
Wednesday, May 25th
2:30 pm | Driving Experimental Trial Design in ALS to Evaluate Multiple Interventions
Michael Benatar
Professor of Neurology
University of Miami
Day Two
Thursday, May 26th
11:30 am | Characterizing Pre-symptomatic ALS to Identify Opportunities for Early Therapeutic Intervention
Miroslaw Brys
Senior Director, Neurodegeneration Clinical Head
Eli Lilly & Company
Day Two
Thursday, May 26th
12:00 pm | SARM1 Inhibition as a Potential Therapeutic Strategy in ALS
Neil Cashman
Chief Scientific Officer & Co-founder
ProMIS Neurosciences
Day Two
Thursday, May 26th
4:30 pm | Chair’s closing remarks
2:00 pm | Generating Effective Therapeutic Strategies for Sporadic Disease with Gene Therapies in ALS
8:25 am | Chair’s Opening Remarks
Olivier Hermine
Chief Scientific Officer
AB Science
Day Two
Thursday, May 26th
3:30 pm | Exploring Mastocytosis & Kinases as the Basis of the History of Masitinib in ALS Mechanism of Action & Reviewing Clinical Results
11:00 am | Panel Discussion: Mechanisms, Targets, & Therapeutic Potential: Dissecting Exciting Opportunities to Drive Novel Therapeutic Strategies
Peter Vanderklish
Chief Scientific Officer
Spinogenix
Day Two
Thursday, May 26th
4:00 pm | Developing a Synaptic Regenerative Therapy in ALS Using a Novel Spinogenic Small Molecule
Ralph Kern
President & Chief Medical Officer
Brainstorm Cell Therapeutics
Day One
Wednesday, May 25th
5:00 pm | Chair’s Closing Remarks
9:30 am | Advancing Novel CSF Biomarkers to Evaluate ALS Target Engagement & Improve Therapeutic Outcomes
8:25 am | Chair’s Opening Remarks
Robert Bowser
Chief Scientific Officer, Professor & Chair of Translational Neuroscience
Barrow Neurological Institute
Day One
Wednesday, May 25th
2:00 pm | Panel Discussion: Refining Sensitive Primary Outcome Measures & Navigating Innovative Trial Design in ALS
11:30 am | Validating Biomarkers & Use in Clinical Trials to Demonstrate Target Engagement & Eligibility Criteria for Enrollment
Robert Scannevin
Chief Scientific Officer
Verge Genomics
Day Two
Thursday, May 26th
9:30 am | Revolutionizing Discovery & Development of ALS Therapeutics Using Transformational, AI-Powered ‘All-in-Human’ Platforms
Stacy Rudnicki
Vice President, Clinical Research
Cytokinetics
Day One
Wednesday, May 25th
3:30 pm | Rethinking Inclusion & Exclusion Criteria: Should we be Dissecting Patient Heterogeneity?
Stephanie Fradette
Senior Medical Director, Clinical Development
Biogen
Day One
Wednesday, May 25th
2:00 pm | Panel Discussion: Refining Sensitive Primary Outcome Measures & Navigating Innovative Trial Design in ALS
8:30 am | Interrogating Neurofilament as a Marker of Disease Activity & Treatment Response
Thomas Holm Pedersen
Chief Executive Officer
NMD Pharma
Day Two
Thursday, May 26th
2:30 pm | Stratifying ALS Patients into Clinically Relevant Subpopulations to Develop Targeted Therapeutics
11:00 am | Panel Discussion: Mechanisms, Targets, & Therapeutic Potential: Dissecting Exciting Opportunities to Drive Novel Therapeutic Strategies
Kelley Erb
Director, Digital & Quantitative Medicine
Biogen